CELC · Celcuity Inc.
$88.34
-4.41% last session
End-of-day data · updated 2026-07-25
Market cap
$4B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
86.1
Dividend yield
—
Beta
0.16
Avg volume
2M
Employees
0K
2D change
-6.47%
5D change
-6.10%
10D change
-9.71%
30D change
-13.87%
60D change
-38.46%
MTD change
-20.93%
YTD change
-17.16%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CELC
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-15
Latest call per bank · past 12 months
Wells Fargo
Overweight$166
+87.9% vs priceJefferies
Buy$134
+51.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-15 | Citizens | Maintains | Market Outperform | $160 → $177 |
| 2026-07-15 | HC Wainwright & Co. | Maintains | Buy | $145 → $155 |
| 2026-06-03 | Craig-Hallum | Maintains | Buy | $189 → $171 |
| 2026-06-03 | Wells Fargo | Maintains | Overweight | $183 → $166 |
| 2026-06-03 | HC Wainwright & Co. | Maintains | Buy | $185 → $145 |
| 2026-05-18 | HC Wainwright & Co. | Maintains | Buy | $165 → $185 |
| 2026-05-15 | Wells Fargo | Maintains | Overweight | $150 → $183 |
| 2026-05-15 | Needham | Reiterates | Buy | $157 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 37 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 19.8% below the 50-day MA ($105.34).
- Price vs 200-day MA: Trading 17.9% below the 200-day MA ($102.83).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.56) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($13.77) and high ($144.98).
CELC Price Chart
Loading chart for CELC…
Fundamentals
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.